Phecda Medicine mitophagy inducer

Phecda Medicine's mitophagy inducer is a preclinical small-molecule therapeutic designed to selectively trigger mitochondrial autophagy (mitophagy). The drug specifically targets damaged mitochondria for degradation, thereby maintaining cellular homeostasis and preventing the accumulation of dysfunctional organelles that contribute to disease progression. Developed by Phecda Medicine (Hangzhou Phecda Medicine Biotechnology), this compound is being explored for its potential in treating a broad spectrum of conditions, including neurological, cardiovascular, liver, and kidney diseases, as well as diabetes and cancers associated with the DNA damage response (DDR). By restoring mitochondrial quality control, the therapy aims to address the underlying pathophysiology of these diverse degenerative and metabolic disorders.